Valve-in-valve transcatheter aortic valve replacement (TAVR) may be a beneficial therapeutic alternative to reoperation in patients with failed aortic bioprostheses, according to the results of the PARTNER II Valve-in-Valve Registry trial, presented Oct. 15 at TCT 2015.

John G. Webb, MD, FACC, and Danny Dvir, MD, et al., evaluated the safety and efficacy of valve-in-valve TAVR with the SAPIEN XT in patients with failed surgical bioprosthetic valves, with the primary endpoint of one-year mortality. Patients included in the trial had symptomatic severe stenosis or regurgitation of a surgical aortic tissue valve and were at high-risk for reoperation. A majority of patients (95.5 percent) were categorized as class 3 or 4 on the New York Heart Association’s (NYHA) heart failure functional classification at baseline.

The results of the study demonstrated the benefits of valve-in-valve TAVR using the SAPIEN XT in this patient population. At one-year follow-up, all-cause mortality was 13.4 percent, while 88 percent were either class 1 or 2 in the NYHA’s functional classification.

The authors of the study note that valve-in-valve TAVR “has emerged as a viable alternative for patients with failing surgical bioprosthetic valves.”

Clinical Topics: Cardiac Surgery, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Valvular Heart Disease, Aortic Surgery, Cardiac Surgery and Heart Failure, Cardiac Surgery and VHD, Acute Heart Failure, Interventions and Structural Heart Disease

Keywords: Transcatheter Cardiovascular Therapeutics, Aortic Valve, Aortic Valve Stenosis, Heart Valve Prosthesis Implantation, Registries, Bioprosthesis, Constriction, Pathologic, Heart Failure, Reoperation, Transcatheter Aortic Valve Replacement

< Back to Listings